ALKS - Alkermes Plc.

Insider Sale by Hopkinson Craig C. (EVP R, D, Chief Medical Office)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Hopkinson Craig C., serving as EVP R, D, Chief Medical Office at Alkermes Plc. (ALKS), sold 9,000 shares at $29.72 per share, for a total transaction value of $267,485.00. Following this transaction, Hopkinson Craig C. now holds 89,389 shares of ALKS.

This sale represents a 9.00% decrease in Hopkinson Craig C.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Alkermes Plc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Hopkinson Craig C.

Hopkinson Craig C.

EVP R, D, Chief Medical Office

Craig C. Hopkinson, M.D. is Executive Vice President, Research & Development and Chief Medical Officer at Alkermes plc (ALKS), a role he has held since January 2020, after joining the company in May 2017 as Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs.[[1]](https://www.alkermes.com/about-us/leadership)[[2]](https://fintool.com/app/research/companies/ALKS/people/craig-c-hopkinson)[[3]](https://www.biospace.com/alkermes-appoints-b-craig-hopkinson-b-m-d-as-chief-medical-officer-and-senior-vice-president-clinical-development-and-medical-affairs)[[4]](https://www.alkermes.com/about-us/leadership/leaders/craig-hopkinson-m-d) Under his leadership, Alkermes has advanced its orexin programs, achieved FY2024 revenues exceeding $1.5B, EBITDA of $452M, GAAP net income of $372M from continuing operations, retired all debt, and repurchased ~$200M in shares.[[2]](https://fintool.com/app/research/companies/ALKS/people/craig-c-hopkinson) As a corporate insider, he has recently traded ALKS stock and maintains compliance with stock ownership guidelines.[[2]](https://fintool.com/app/research/companies/ALKS/people/craig-c-hopkinson)

View full insider profile →

Trade Price

$29.72

Quantity

9,000

Total Value

$267,485.00

Shares Owned

89,389

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Alkermes Plc.

Company Overview

No company information available
View news mentioning ALKS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4501153

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime